Aadi Bioscience, Inc.: management transactions · United States · SEC (Form 4)

About Aadi Bioscience, Inc.

Aadi Bioscience, Inc. was a United States-based biopharmaceutical company listed on the NASDAQ, with a focus on precision oncology and genetically defined cancers. The company built its identity around targeting tumors driven by alterations in the mTOR pathway, particularly in very rare oncology settings where clinical differentiation and regulatory exclusivity can matter more than scale. Historically, the company’s headquarters were in Los Angeles, California, while corporate contact information also referenced a Headquarters Plaza address, consistent with the operating footprint of a U.S. biotech transitioning from development to commercialization. ([aadibio.com](https://www.aadibio.com/aadi-bioscience-announces-u-s-commercial-launch-and-availability-of-fyarro-for-the-treatment-of-adult-patients-with-locally-advanced-unresectable-or-metastatic-malignant-pecoma/?utm_source=openai)) Aadi’s core business centered on FYARRO, its lead product, which is nab-sirolimus, a sirolimus formulation bound to albumin. FYARRO was developed for genetically defined cancers and ultimately received FDA approval in the United States for adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). That approval was a defining milestone because PEComa is an ultra-rare sarcoma with limited treatment options, and Aadi positioned FYARRO as a therapy tailored to the biology of the disease rather than a broad oncology asset. The company also highlighted clinical data from its AMPECT registration trial and broader scientific work around TSC1/TSC2-altered tumors and mTOR biology. ([aadibio.com](https://www.aadibio.com/aadi-bioscience-announces-fda-approval-of-its-first-product-fyarro-for-patients-with-locally-advanced-unresectable-or-metastatic-malignant-perivascular-epithelioid-cell-tumor-pecoma/?utm_source=openai)) From a competitive standpoint, Aadi occupied a niche position in rare oncology. It was not competing head-on with large oncology franchises, but rather operating in a specialized segment where the main challenge is the limited patient population and the commercial complexity of ultra-rare cancers. Its differentiation came from product mechanism, biomarker logic, and regulatory recognition, including FDA orphan-related and breakthrough-style support for the original development program. For investors, this made Aadi more of a high-conviction, single-asset biotech story than a diversified platform company. ([aadibio.com](https://www.aadibio.com/aadi-bioscience-recieves-fda-orphan-product-development-grant-for-treatment-of-advanced-pecoma-2/?utm_source=openai)) Geographically, the company’s operations were primarily U.S.-centric, with U.S. commercialization and U.S.-focused medical and regulatory activities. While the scientific relevance of mTOR-targeted rare cancer therapies is global, Aadi’s business model and near-term revenue opportunity were rooted in the United States market. ([aadibio.com](https://www.aadibio.com/aadi-bioscience-announces-u-s-commercial-launch-and-availability-of-fyarro-for-the-treatment-of-adult-patients-with-locally-advanced-unresectable-or-metastatic-malignant-pecoma/?utm_source=openai)) A major recent development for market participants is that Aadi agreed in December 2024 to sell the FYARRO business to Kaken for $100 million, and that divestiture was later completed in 2025. Following the transaction, the company changed its name to Whitehawk Therapeutics, Inc. and no longer operated the FYARRO business. For anyone analyzing historical AADI insider filings on SEC Form 4, this corporate reset is highly material: the issuer’s strategy, asset base, and investment profile changed substantially after the divestiture. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1422142/000095017024139724/xslSCHEDULE_13D_X01/primary_doc.xml?utm_source=openai))